Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9Y5N5
UPID:
N6MT1_HUMAN
Alternative names:
HemK methyltransferase family member 2; Lysine N-methyltransferase 9; Methylarsonite methyltransferase N6AMT1; Protein N(5)-glutamine methyltransferase
Alternative UPACC:
Q9Y5N5; B2RA97; Q96F73
Background:
Methyltransferase N6AMT1, known as HemK methyltransferase family member 2, Lysine N-methyltransferase 9, and Methylarsonite methyltransferase, plays a crucial role in protein methylation. It acts as a catalytic subunit in a heterodimer with TRMT112, targeting 'Lys-12' of histone H4 and a specific Glu residue in proteins, influencing cell cycle regulators and protein function. Additionally, it's involved in arsenic toxicity modulation through methylation processes.
Therapeutic significance:
Understanding the role of Methyltransferase N6AMT1 could open doors to potential therapeutic strategies.